• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Poland Pharmaceuticals and Healthcare Report Q3 2012 - Product Image

Poland Pharmaceuticals and Healthcare Report Q3 2012

  • Published: June 2012
  • Region: Poland
  • 104 Pages
  • Business Monitor International

The Poland Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Poland's pharmaceuticals and healthcare industry.

BMI View: Despite numerous challenges, we continue to believe Poland is the most attractive pharmaceutical market in Central and Eastern Europe (CEE). While the long-awaited Drug Reimbursement Act introduced in Q112 faced fierce opposition from the public and members of the healthcare profession, and also resulted in volatility of pharmaceutical spending, we maintain our view of positive growth for 2012, projecting 1.6% year-on-year (y-o-y) expansion. Headline Expenditure Projections

- Pharmaceuticals: PLN33.37bn (US$11.26bn) in 2011 to PLN33.91bn (US$10.72bn) in 2012; +1.6% in local currency terms and -4.8% in US dollar terms. Local currency forecast unchanged since Q212.

- Healthcare: PLN111.08bn (US$37.51bn) in 2011 to PLN117.00bn (US$36.99bn) in 2012; +5.2% in local currency terms and -1.4% in US dollar terms. Local currency forecast slightly higher since Q212 READ MORE >

Executive Summary 5

SWOT Analysis 7

Poland Pharmaceuticals Industry SWOT 7

Poland Political SWOT 8

Poland Economic SWOT 8

Poland Business Environment SWOT 9

Pharmaceutical Risk/Reward Ratings 10
Table: Central And Eastern Europe Pharmaceuticals Risk/Reward Ratings, Q312 10

Rewards 12

Risks 13

Poland – Market Summary 15

Regulatory Regime 16

Advertising Regulations 17

Other Regulatory Developments 18

Intellectual Property Regime 18

Intellectual Property Shortcomings 19

Pricing And Reimbursement Regime 20

Pricing Policies 21

Drug Price Inflation 22

Reimbursement Policies 23

Reimbursement Regime Changes 24

Industry Trends And Developments 28

Epidemiology 28

Healthcare System 29

Hospital Privatisation 30

Health Insurance 32

Research & Development 33

Clinical Trials 34

Developments In The Clinical Trials Sector 35

Medical Devices 36

Industry Forecast Scenario 38

Overall Market Forecast 38
Table: Pharmaceutical Sales, 2008-2016 40

Key Growth Factors – Industry 41
Table: Total Healthcare Expenditure, 2008-2016 44
Table: Government Healthcare Expenditure, 2008-2016 44
Table: Private Healthcare Expenditure, 2008-2016 45

Key Growth Factors – Macroeconomic 46
Table: GDP By Expenditure, Real Growth, 2008-2016 52

Prescription Drug Market Forecast 53
Table: Prescription Drug Sales, 2008-2016 54

Patented Drug Market Forecast 55
Table: Patented Drug Sales, 2008-2016 56

Generic Drug Market Forecast 57
Table: Generic Drug Sales, 2008-2016 58

OTC Medicine Market Forecast 59
Table: OTC Medicine Sales, 2008-2016 60
Table: OTC Medicne Sales By Subsector, 2007-2010 61

Pharmaceutical Trade Forecast 62
Table: Pharmaceutical Trade, 2008-2016 64

Medical Device Market Forecast 65
Table: Medical Devices Sales, 2008-2016 66

Key Risks To our Forecast Scenario 67

Competitive Landscape 68

Pharmaceutical Industry 68

Domestic Industry 68

Domestic Company Developments 69

Foreign Industry 72

Foreign Company Developments 73

Pharmaceutical Wholesale Sector 74

Pharmaceutical Retail Sector 76
Table: Number Of Pharmacies In Poland, 2004-2009 78

Company Profiles 79

Local Companies 79

Polpharma 79

Bioton 81

Multinational Companies 84

GlaxoSmithKline 84

Eli Lilly 86

Gedeon Richter 88

Krka 90

Lek (Sandoz/Novartis) 92

Demographic Outlook 94
Table: Population By Age Group, 1990-2020 (‘000) 95
Table: Population By Age Group, 1990-2020 (% of total) 96
Table: Key Population Ratios, 1990-2020 97
Table: Rural And Urban Population, 1990-2020 97

Glossary 98

BMI Methodology 100

How We Generate Our Pharmaceutical Industry Forecasts 100

Pharmaceutical Risk/Reward Ratings Methodology 101

Ratings Overview 101
Table: Pharmaceutical Risk/Reward Indicators 102

Weighting 103
Table: Weighting Of Components 103

Sources 103

Polpharma , Bioton , , GlaxoSmithKline , Eli Lilly , Gedeon Richter , Krka , Lek (Sandoz/Novartis) ,

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos